Associations - ALK rearrangement

ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A2 - Guideline	alectinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Sensitive: A2 - Guideline	ALK inhibitor Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A2 - Guideline	ceritinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A2 - Guideline	lorlatinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A2 - Guideline	brigatinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ceritinib Sensitive: B - Late Trials	ceritinib Sensitive: B - Late Trials
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: C2 – Inclusion Criteria	nivolumab Sensitive: C2 – Inclusion Criteria
ALK rearrangement ALK rearrangement	Solid Tumor Solid Tumor	ALK rearrangement ALK rearrangement	Solid Tumor Solid Tumor	alectinib Sensitive: C2 – Inclusion Criteria	alectinib Sensitive: C2 – Inclusion Criteria
ALK rearrangement ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	crizotinib Sensitive: C2 – Inclusion Criteria	crizotinib Sensitive: C2 – Inclusion Criteria
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	bevacizumab + alectinib Sensitive: C2 – Inclusion Criteria	bevacizumab + alectinib Sensitive: C2 – Inclusion Criteria
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ceritinib + ribociclib Sensitive: C2 – Inclusion Criteria	ceritinib + ribociclib Sensitive: C2 – Inclusion Criteria
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: C2 – Inclusion Criteria	durvalumab Sensitive: C2 – Inclusion Criteria
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	bevacizumab + crizotinib Sensitive: C3 – Early Trials	bevacizumab + crizotinib Sensitive: C3 – Early Trials
ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Resistant: C3 – Early Trials	PD-L1 inhibitor Resistant: C3 – Early Trials
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
ALK rearrangement ALK rearrangement	Non-Hodgkin’s Lymphoma NHL	ALK rearrangement ALK rearrangement	Non-Hodgkin’s Lymphoma NHL	ceritinib Sensitive: C3 – Early Trials	ceritinib Sensitive: C3 – Early Trials
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	IPI-504 Sensitive: C3 – Early Trials	IPI-504 Sensitive: C3 – Early Trials
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ipilimumab Sensitive: C3 – Early Trials	ipilimumab Sensitive: C3 – Early Trials
ALK rearrangement ALK rearrangement	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	ALK rearrangement ALK rearrangement	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	ALK inhibitor Sensitive: C3 – Early Trials	ALK inhibitor Sensitive: C3 – Early Trials
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	WX-0593 Sensitive: C3 – Early Trials	WX-0593 Sensitive: C3 – Early Trials
ALK rearrangement ALK rearrangement	Renal Cell Carcinoma RCC	ALK rearrangement ALK rearrangement	Renal Cell Carcinoma RCC	crizotinib Sensitive: C4 – Case Studies	crizotinib Sensitive: C4 – Case Studies
ALK rearrangement ALK rearrangement	Sarcoma Sarcoma	ALK rearrangement ALK rearrangement	Sarcoma Sarcoma	crizotinib Sensitive: C4 – Case Studies	crizotinib Sensitive: C4 – Case Studies
ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	crizotinib Resistant: C4 – Case Studies	crizotinib Resistant: C4 – Case Studies
ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	bevacizumab Sensitive: C4 – Case Studies	bevacizumab Sensitive: C4 – Case Studies
ALK rearrangement ALK rearrangement	Renal Cell Carcinoma RCC	ALK rearrangement ALK rearrangement	Renal Cell Carcinoma RCC	alectinib Sensitive: C4 – Case Studies	alectinib Sensitive: C4 – Case Studies
ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	alectinib Sensitive: C4 – Case Studies	alectinib Sensitive: C4 – Case Studies
ALK rearrangement ALK rearrangement	Lung Cancer Lung Cancer	ALK rearrangement ALK rearrangement	Lung Cancer Lung Cancer	BMS-722782 Sensitive: D – Preclinical	BMS-722782 Sensitive: D – Preclinical
ALK rearrangement ALK rearrangement	Small Cell Lung Cancer Small Cell Lung Cancer	ALK rearrangement ALK rearrangement	Small Cell Lung Cancer Small Cell Lung Cancer	alectinib Sensitive: D – Preclinical	alectinib Sensitive: D – Preclinical
ALK rearrangement ALK rearrangement	Lung Cancer Lung Cancer	ALK rearrangement ALK rearrangement	Lung Cancer Lung Cancer	alectinib + YHO-1701 Sensitive: D – Preclinical	alectinib + YHO-1701 Sensitive: D – Preclinical